<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2248836&amp;fmt=gif">
MIM Software Inc.
 

MIM Software Inc.

MIM SurePlan™ MRT and MIM SurePlan™ LiverY90

Stand out in Theranostics

Stand out in Theranostics

Personalized Dosimetry is the Fastest way to Show Proof of Value1

Conventional approaches to dosimetry rely on outdated methods that don’t scale and lead to inefficiencies that departments won’t tolerate as demand for therapies continues to grow. These outmoded methods further widen the gap that Nuclear Medicine departments face as they seek to adopt theranostics – putting them even further behind the curve.

Nuclear Medicine Departments are Changing

A Shift to Theranostics Presents Unique Challenges

Nuclear Medicine Departments are Changing - A Shift to Theranostics Presents Unique Challenges

Current and Future Nuclear Theranostic Approaches1

 
Nuclear Theranostic Pair Target Application
68Ga- and 177Lu-DOTATATE Somatostatin receptors NETs
68Ga- and 177Lu-PSMA PSMA Prostate cancer
123I- and 131I-iobenguane Norepinephrine reuptake transporter Neuroblastoma, paraganglioma, pheochromocytoma
68Ga- and 177Lu-FAPI Fibroblast activation protein Multiple cancers
68Ga- and 177Lu-3BP-227 NTR1 antagonist Neurotensin receptor 1 Pancreatic cancer
124I- and 131I-girentuximab Carbonic anhydrase 9 Renal cell cancer
123I- and 131I-iodine Sodium/iodide symporter Thyroid diseases

 

Increase in Therapies

Lutathera treats a rare disease, and 30,000 annual cycles of this treatment are expected. Future approaches, such as PSMA therapy, present a larger opportunity (~160 cycles estimated annually2).

Pressure to Demonstrate Value

Conventional approaches often take several months to determine treatment effectiveness, leaving clinicians and patients in the dark. Better information is needed to guide treatment decisions.

Emphasis on Patient Retention

Hospitals are under pressure to retain patients – and will allocate resources to departments that demonstrate the most value.

MIM SurePlan™ MRT

Advancing Molecular Radiotherapy

Calculating patient-specific dose doesn’t need to add significant time to your workflow. MIM SurePlan MRT provides effective dosimetry, organ and tumor segmentation, deformable registration, and communication tools that help reduce clinical effort — in a single solution.

 

MIM SurePlan™ MRT

Timesaving Tools

Automated segmentation can significantly reduce the time required to generate organ volumes such as the kidneys and liver. Industry-leading PET and SPECT segmentation tools are available for tumors and other volumes of interest (VOI).

Multi-Tracer Theranostics Support

Multiple Molecular Radiotherapy tracers such as Lutathera Lu-177 dotatate, Azedra I-131 iobenguane, Hicon I-131 NAI for thyroid, and more can be imaged with MIM SurePlan MRT, providing confirmation of dose delivery in the patient.

Quantitative SPECT and Planar Corrections

Vendor-neutral quantitative SPECT reconstruction is available for dosimetry in SPECTRA Quant™. Now, clinicians can generate quantitative images off the imaging so dose can be measured as opposed to measuring the amount of activity.

deformable

Compare PET, SPECT, CT, MRI, and CBCT within MIM’s intuitive interface. Multi-modality rigid and deformable fusion ensure consistency when there are differences in position, size, and organ movement.

voxel-based dosimetry_

MIM SurePlan MRT provides voxel-based absorbed dose calculation using the patient’s own anatomy. Calculate isodose curves/DVH on SPECT using voxel S-value scheme in MIRD Pamphlet No.17. MIM’s automated tools for serial exam comparison make therapy response evaluation viable.

 

Supply more dosimetric information to referring physicians using the integrated reporting solution with images and statistics. Dictated text can be pulled into reports from PowerScribe® 360 and exported to PDF or DICOM structured reports.

Additional Resources

See how the experts are using dosimetry and radionuclide therapies in the clinic.

 

MIM SurePlan™ LiverY90

A Comprehensive Solution for Y90

MIM SurePlan LiverY90 provides timesaving tools for liver and tumor segmentation, deformable registration, and post-treatment dosimetry using Y90-PET and Bremsstrahlung SPECT.

 

MIM SurePlan LiverY90™

Timesaving Tools

MIM SurePlan LiverY90 is specifically engineered for Y90, making efficiency a top priority. A recent study3 in the Journal of Nuclear Medicine demonstrated a 70% reduction in time compared to manual outlining of the liver.

Lobe and Liver Segmentation

Segment the lobe and liver with atlas-based segmentation and Contour CoPilot™.

Post-Op Dosimetry

Calculate dose using Y90-PET and Bremsstrahlung SPECT. Calculate isodose curves/DVH on PET/SPECT using Local Disposition Method or MIRD Kernal.

Additional Resources

See how the experts are using MIM SurePlan LiverY90 in the clinic.

 

Footnotes

  1. Begum, Nusrat J, et al., "The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides." Journal of Nuclear Medicine 59, no. 6 (2018): 929–33.
  2. Czernin, Johannes, et al., "The Future of Nuclear Medicine as an Independent Specialty." Journal of Nuclear Medicine 60, no. 2 (2019): 3S-12S.
  3. M Horvat, et al., Time Savings of a Multi-Atlas Approach for Liver Segmentation. Journal of Nuclear Medicine 55, no.1 (2014): 1523.

 

MIM Software

Learn how MIM is Improving Personalized Dosimetry

Schedule a Meeting
MIM Software Inc.

MIM Software Inc. provides practical imaging solutions in the fields of radiation oncology, radiology, nuclear medicine, neuroimaging, and cardiac imaging. MIM offers solutions for PC and Mac® workstations, as well as mobile iOS and cloud-based platforms. MIM is a privately held company that sells its products globally to imaging centers, hospitals, specialty clinics, research organizations, and pharmaceutical companies.

Privacy Policy
Terms of Use

Copyright © 2020 MIM Software Inc. All Rights Reserved.